Omogući pristup Omogući pristup

Search Results

Korporativna filozofija

Korporativna filozofija Misija Cilj naše misije je bolje zdravlje i svjetlija budućnost za ljude širom svijeta putem vrhunskih inovacija u medicini Vizija za 2025. Služimo potrebama naših pacijenata, bez obzira na to gdje se nalaze. Mi filozofijom Takedaizma pridobijamo povjerenje društva i klijenata. Prepoznati smo kao najbolji zbog agilnosti i inovativnosti, kvaliteta koji nam pomažu da izgradimo kontinuitet u ostvarenju rasta iz godine u godinu. Vrijednosti Strateški putokaz Naša strateška mapa puta oslanja se na četiri ključne postavke iz kojih proizilaze koraci za ostvarivanje Vizije 2025. Fokusirat ćemo se na vrijednosti, ljude, istraživanje i razvoj te poslovni učinak kao pretpostavke za naš napredak u skladu s Vizijom 2025. Sprovodit ćemo redovne revizije kako bismo pratili postignuti napredak i ostali na zacrtanom putu realizacije Vizije 2025. Postavili smo određene ciljeve, planove i indikatore uspješnosti da bismo zadovoljili potrebe naših pacijenata, ma gdje se nalazili, te stekli povjerenje zajednice i naših kupaca. Vrijednosti Takedaizam (integritet, pravednost, poštenje, istrajnost) i pacijenti, povjerenje, reputacija i poslovnost, duboko su utkani u naš način poslovanja. Oslanjamo sa na njih pri donošenju odluka i poduzimanju koraka da bi naša predanost kvalitetu i ispravnom poslovanju ostala neupitna – u svakom trenutku. Ljudi Kompanija Takeda gaji nepokolebljivu predanost pacijentima i izgradnji organizacije usmjerene na potrebe pacijenata i kupaca. Naše lokalne organizacije osnažene su da na najbolji način odgovore potrebama pacijenata i kupaca. Naši zaposlenici temelj su našeg uspjeha. Gradimo diverzificirano, inkluzivno, sigurno, otvoreno radno okruženje u kojem se potiče saradnja i u kojem zaposlenici mogu dati svoj doprinos, postići rezultate i individualni napredak. Lideri kompanije Takeda demonstriraju strateško razmišljanje, pronalaze inovativne načine pružanja usluga pacijentima, grade povjerenje u društvu, jačaju našu reputaciju i šire poslovanje. Oni stvaraju okruženje koje pruža inspiraciju i omogućava saradnju među ljudima i napredovanje organizacije. Usredsređuju se na naše definirane prioritete i postižu vrhunske rezultate. I jačaju sposobnosti naše organizacije, kako danas tako i u budućnosti. Istraživanje i razvoj (R&D) Pokretač kompanije Takeda je mehanizam za istraživanje i razvoj svjetskog ranga koji preobražava naučna dostignuća u lijekove i tako mijenja živote pacijenata. Kao kompanija pokretana istraživanjem i razvojem, svoje istraživačke aktivnosti fokusiramo na oblasti u kojima želimo biti predvodnici inovacija. Naši istraživački centri fokusirani su na četiri ključne terapijske oblasti, onkologiju, gastroenterologiju, rijetke bolesti i neurologiju. Naš visokoproduktivni mehanizam istraživanja i razvoja koristi kombinovani pristup internih i eksternih inovacija u svrhu ostvarivanja održivog dotoka inovativnih rješenja. Uz to, naša je ambicija da budemo jedan od najpoželjnijih poslovnih partnera u našoj djelatnosti. PoslovanjeUčinak Kompanija Takeda je usmjerena na dugoročni profitabilni rast kroz šest pokretača poslovanja. Oni uključuju naše četiri ključne terapijske oblasti, onkologiju, gastroenterologiju, rijetke bolesti i neurologiju, kao i terapije zasnovane na derivatima plazme (PDT) te vakcine. Stroga finansijska disciplina pomaže u održavanju profitabilnog rasta i pružanju najsveobuhvatnijeg mogućeg pristupa našim lijekovima. Sve nabrojano nam omogućava da budemo konkurentni i učinimo više za pacijente sa nezadovoljenim medicinskim potrebama. Povezani sadržaj Osnovne komponente naše korporativne filozofije uključuju našu misiju, viziju, vrijednosti i strateški putokaz. Saznajte više Informacije o kompaniji Naše priče Istorijat SAZNAJTE VIŠE SAZNAJTE VIŠE SAZNAJTE VIŠE https://bit.ly/2FBWSYd
www.takeda.com/bs-ba/who-we-are/korporativna-filozofija/

Ko smo mi

O kompaniji Takeda O kompaniji Takeda O kompaniji Takeda Kako možemo učiniti nešto više za naše pacijente?U kompaniji Takeda sve se vrti oko ovog pitanja. Kako možemo učiniti nešto više za naše pacijente?U kompaniji Takeda sve se vrti oko ovog pitanja. SAZNAJTE VIŠE Saznajte više https://bit.ly/37y1aLp
www.takeda.com/bs-ba/who-we-are/

Više od lijekova

Pristup jačanju globalnih zdravstvenih sistema koji uključuje više od lijekova Pristup jačanju globalnih zdravstvenih sistema koji uključuje više od lijekova Pristup jačanju globalnih zdravstvenih sistema koji uključuje više od lijekova SAZNAJTE VIŠE About Takeda’s AtM strategy It's estimated that one in three people in developing countries can't get essential medicines on a regular basis. Even in countries considered developed, patients who have to pay for medical treatment out of pocket often find it hard to access or afford the healthcare and medicines they need. Geographic hurdles hinder remote populations, substandard healthcare infrastructures limit reliable diagnoses, and precise medical knowledge is restricted to a small number of specialists. These barriers make it difficult to treat those in serious need. While improvements in care, clinical innovations, and drug deliveries continue to advance, access to these advancements remains an underlying challenge to the health of many people around the world. A Focus on Unmet Needs As part of the global community, Takeda has refocused its efforts and approach to Access to Medicines (AtM). For many years, the company has provided product, funding, and access based on regional needs. The new AtM strategy builds on that by focusing on geographies and therapy areas with the highest unmet need. Takeda’s AtM strategy to improve these current situations Takeda's AtM strategy is guided by the corporate patient-centric philosophy and a legacy of helping others in need. Of the 38 million people who die from non-communicable diseases each year, three quarters - or 28 million - of these deaths occur in low- and middle-income countries. Center of Excellence in Africa AtM programs reflect the variety of healthcare needs - from pricing strategies and helping improve living standards to vaccine development and diagnostic capabilities. In Sub-Saharan Africa (SSA), Takeda has initiated a not-for-profit approach to accessibility where a Center of Excellence (CoE) will provide sustainability for diagnosis and treatment of oncology/hematology diseases. This CoE, located in Kenya, will also work with local partners to make select primary care medicines more broadly accessible across the region. Global Patient Assistance Programs A cornerstone of Takeda's AtM strategy is the Patient Assistance Programs (PAP), which provide financial support to those patients who are unable to pay for the treatments they need. Many of these PAPs will see the implementation of tailored pricing in the Emerging Markets where patients typically pay for their healthcare "out of pocket" due to lack of reimbursement. The goal is that any patient diagnosed and prescribed Takeda oncology or GI medicines will be able to access treatment on a "pay what you can afford" basis. Takeda has already launched a PAP in Thailand and aims to expand in ten more countries across South East Asia, Latin America, and the Middle East by the end of the year. Another pillar of Takeda’s AtM strategy Another pillar of Takeda's AtM strategy is corporate social responsibility programs through which the company makes contributions to disproportionately affected populations and areas with evolving healthcare systems. As part of the strategy to "go beyond medicines," these programs are designed to prevent diseases and build local capacity in countries with evolving healthcare systems like Brazil, Ukraine, and the Philippines. In Brazil, for example, this activity will include the creation of a network of infusion centers in small cities across the country. Takeda is committed to helping advance patient health via collaborative, affordability-based approaches that bring together key stakeholders to ensure our latest, innovative medicines reach the patients that need them. We have rolled-out comprehensive patient assistance programs in a number of Emerging Markets. Our aspiration is that eligible patients who are prescribed Takeda's potentially life-saving medicines will be able to get access to them. Related Content Saznajte više Pristup jačanju globalnih zdravstvenih sistema koji uključuje više od lijekova | Njega | Takeda Širom Svijeta Pristup jačanju globalnih zdravstvenih sistema koji uključuje više od lijekova Pristup jačanju globalnih zdravstvenih sistema koji uključuje više od lijekova | Njega | Takeda Širom Svijeta Pristup jačanju globalnih zdravstvenih sistema koji uključuje više od lijekova https://bit.ly/2P5vKVH
www.takeda.com/bs-ba/our-stories/njega/vie-od-lijekova/

Ključni elementi i suština naših inovacija

Ključni elementi i suština naših inovacija Ključni elementi i suština naših inovacija Ključni elementi i suština naših inovacija SAZNAJTE VIŠE Technology, Insight, and Passion When prescribed medication by your doctor, it’s only right that you pay more attention to how many tablets to take and when to take them, than to what they actually contain. Modern-day drugs are often the result of decades of rigorous research, countless failures in the lab, and perhaps a surprising breakthrough – and all of this before they are submitted for the laborious testing required to gain regulatory approval. But take a closer look at the label, and amongst the ingredients, you will likely find one or more of a number of essential elements—Active Pharmaceutical Ingredients (APIs)—and it’s these that give what may just be a small white tablet the ability to transform your life. The development of new APIs is never a routine process. With the potential for success sometimes not only years but decades away in the future, it requires our scientists to maintain both extraordinary passion and a deep sense of commitment to the mission. With multiple setbacks to be expected along the way, tenacity is a must, as is the flexibility to recognize new possibilities that may arise from seeming failure. Naturally, as a company, we are united behind our researchers in this mission to find new cures and go to great lengths to support them in the discovery and development of new APIs. Our cutting-edge technologies and global facilities constantly evolve to take advantage of new breakthroughs. The sharing of expertise by employees who have decades of experience with younger colleagues is an essential part of our work culture, playing an important role in both fostering strong community relations, and also in ensuring we maintain the quality of our products. From the Lab to the Patient Once an API has been developed, refined, and tested, the next challenge is to manufacture it at scale. In impeccably clean rooms, precisely measured combinations of powder and liquid are placed in giant reactors that can hold up to 3,000 liters, heated, filtered, and then dried to create the final product. A single production cycle can produce 100 kilograms of an API, equivalent to around 10 million tablets if each contains 10 milligrams of the substance. Once manufactured—complete with the precisely controlled amount of API—these tablets pass through automated packaging and testing processes, before finally entering the distribution chain. It is only after this lengthy process that they will finally reach you. No label on a bottle of tablets would ever be large enough to tell the full story of the development of the drug. Instead, it may simply list the APIs contained—but you will know that there is much more to it than meets the eye.  Related Content Saznajte više Ključni elementi i suština naših inovacija | Širom Svijeta Ključni elementi i suština naših inovacija Ključni elementi i suština naših inovacija | Širom Svijeta Strengthening our global production network in Oranienburg Takeda Recognized for Commitment to Quality Quality at Takeda Ključni elementi i suština naših inovacija LEARN MORE LEARN MORE LEARN MORE https://takeda.info/3ejjHhr
www.takeda.com/bs-ba/our-stories/inovacije/kljuni-elementi-i-sutina-naih-inovacija/